Novoprotein(SH:688137)2023-04-26 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 43,002,533.69, representing a decrease of 51.05% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was CNY 11,141,255.79, down 72.08% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 83.12% in Q1 2023[9] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.16, reflecting a decline of 78.95%[6] - The weighted average return on equity decreased by 9.97 percentage points to 0.51% in Q1 2023[6] - The company reported a significant decline in revenue primarily due to a drop in unconventional diagnostic antibody sales, but excluding this, business revenue increased by 39% year-on-year[9] - Total operating revenue for Q1 2023 was ¥43,002,533.69, a decrease of 51.0% compared to ¥87,842,857.29 in Q1 2022[18] - Net profit for Q1 2023 was ¥11,140,705.59, down 72.1% from ¥39,962,894.18 in Q1 2022[19] - The company reported a total profit of ¥9,841,111.88 for Q1 2023, down 79.3% from ¥47,556,801.85 in Q1 2022[19] - Basic earnings per share for Q1 2023 were ¥0.16, a decrease of 78.9% from ¥0.76 in Q1 2022[19] Research and Development - Research and development expenses totaled CNY 11,008,017.25, accounting for 25.60% of operating revenue, an increase of 14.58 percentage points[6] - Research and development expenses rose to ¥11,008,017.25 in Q1 2023, compared to ¥9,680,652.72 in Q1 2022, an increase of 13.7%[18] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 2,353,123,774.86, a slight increase of 0.63% from the end of the previous year[6] - As of March 31, 2023, the company's total current assets amounted to RMB 2,149,706,056.96, slightly up from RMB 2,135,154,615.28 at the end of 2022, indicating a growth of approximately 0.03%[15] - The total liabilities of the company as of March 31, 2023, were RMB 141,119,651.87, compared to RMB 138,911,832.07 at the end of 2022, showing a slight increase of approximately 1%[16] - The total assets of the company reached RMB 2,353,123,774.86, up from RMB 2,338,298,078.50, reflecting a growth of about 0.63%[16] - The company's total equity increased to RMB 2,212,004,122.99 from RMB 2,199,386,246.43, marking an increase of approximately 0.67%[16] - The company's accounts receivable decreased to RMB 104,582,842.79 from RMB 118,891,144.58, a decline of about 11.99%[14] - The inventory level rose to RMB 94,403,352.24 from RMB 77,079,735.58, indicating an increase of approximately 22.5%[14] Cash Flow and Investments - Operating cash flow for Q1 2023 increased to ¥23,744,113.03 from ¥7,020,963.80 in Q1 2022, marking a significant improvement[20] - Cash and cash equivalents at the end of Q1 2023 totaled ¥1,485,658,036.01, up from ¥175,867,713.02 at the end of Q1 2022[21] - The company's cash and cash equivalents increased significantly to RMB 1,486,231,440.33 from RMB 929,924,309.17, representing a growth of about 60%[14] - The company generated investment cash inflow of ¥1,150,562,943.82 in Q1 2023, with a net cash flow from investment activities of ¥537,664,522.63[21] - The company reported a significant increase in cash reserves, which may support future investments and operational expansions[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,865[11] Government Subsidies - The company received government subsidies amounting to CNY 581,100.00, which are closely related to its normal business operations[7] Other Information - The company's short-term borrowings and other liabilities were not detailed in the provided data, indicating a focus on maintaining liquidity and managing debt levels[16] - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - The company incurred a foreign exchange loss of ¥51,237.11 in Q1 2023, compared to a loss of ¥158,968.72 in Q1 2022[21]